

Dicerna Pharmaceuticals Investor Relations Department 87 Cambridgepark Drive Cambridge, MA 02140 United States

Visit IR website ☐ Sign-up for Email alerts ☐

NASDAQ: DRNA	
Last Trade:	3.23
Trade Time:	4:00 PM ET Jun 23, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	2.42 - 6.10
Volume	N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Dicerna is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. The Company is using its proprietary GalXC RNAi technology platform to build a broad pipeline in these therapeutic areas.

<u>Dicerna Corporate Fact</u> <u>Sheet(more)</u>

Stock Performance



Press Releases [View all]

Jun 15, 2017

<u>Dicerna Pharmaceuticals, Inc. Reports</u> <u>Inducement Grants Under NASDAQ Listing</u> <u>Rule 5635(c)(4)</u>

Jun 8, 2017

<u>Dicerna Announces Appointment of Ralf</u> <u>Rosskamp, M.D., as Chief Medical Officer</u>

Jun 1, 2017

<u>Dicerna to Present at Jefferies 2017 Global</u> <u>Healthcare Conference</u>

May 8, 2017

<u>Dicerna Reports First Quarter 2017 Financial</u> <u>and Operational Results and Provides</u> <u>Corporate Update</u>

May 1, 2017

Dicerna to Report First Quarter 2017
Financial Results and Host Conference Call
on May 8, 2017

Financials [View all]

Mar 30, 2017 Annual Report (10-K)

May 23, 2017
Proxy Statement (DEF 14A)

May 8, 2017 Quarterly Report (10-Q)

Nov 7, 2016 Quarterly Report (10-Q)

Aug 4, 2016
Quarterly Report (10-Q)